Sirpiglenastat
Peptideexperimental
Clinical trial activity
3 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Aug 31, 2020 (NCT04471415)
Timeline
Indications
Mechanism of action
- GlutamineANTAGONIST
Glutamine antagonist
Chemistry & pharmacology
Loading structure…
SMILES
CC(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(=O)C=[N+]=[N-])C(=O)OC(C)C- Mol. weight
- 441.49 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4650367 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07249372 | Phase 2 | Dec 1, 2025 | New York University |
| NCT06027086 | Phase 1/Phase 2 (Phase 2) | Jan 1, 2024 | Dracen Pharmaceuticals, Fibrolamellar Cancer Foundation, Johns Hopkins University |
| NCT04471415 | Phase 1/Phase 2 (Phase 2) | Aug 31, 2020 | Dracen Pharmaceuticals, HonorHealth Research Institute |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Dracen Pharmaceuticals | For profit | 2 | 1 | 1 | 2020 |
| Fibrolamellar Cancer Foundation | Academic/Hospital | 1 | 0 | 1 | 2024 |
| HonorHealth Research Institute | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Johns Hopkins University | Academic/Hospital | 1 | 1 | 1 | 2024 |
| New York University | Academic/Hospital | 1 | 1 | 1 | 2025 |
5 organizations
Page 1 / 1